Are there any preservatives, adjuvants, or fetal-cell-derived components in COVID-19 vaccines?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
Major COVID-19 vaccine platforms differ on preservatives, adjuvants and use of fetal‑derived cell lines: mRNA vaccines (Pfizer–BioNTech, Moderna) do not use traditional vaccine adjuvants and were not manufactured using fetal‑derived cell lines, while viral‑vector (Janssen/J&J, AstraZeneca) and some protein‑based vaccines have relied on fetal‑origin cell lines at stages of development or production [1] [2] [3]. Thimerosal (a preservative used in some multidose vials) is discussed in public guidance but not widely present in single‑dose COVID vaccine vials; adjuvants such as aluminum are used in some vaccines historically, but the dominant mRNA COVID shots do not contain aluminum adjuvants [4] [5] [3].
1. What “preservatives” are in COVID‑19 vaccines — not a one‑size‑fits‑all answer
Preservatives like thimerosal have historically been used in multidose vaccine vials; public guidance during 2025 notes thimerosal remains a preservative in some multidose influenza vaccines and experts say it is harmless, but that does not mean every COVID‑19 product contains it [4]. Regulatory fact sheets list specific ingredients for each authorized COVID‑19 vaccine and are the definitive public source for a given product’s preservatives; the FDA points readers to those fact sheets for the exact ingredient lists [6]. Available sources do not list a universal preservative across all COVID‑19 vaccines [6] [4].
2. Do COVID‑19 vaccines contain adjuvants such as aluminum?
Adjuvants — compounds added to boost immune response — have been used for decades (aluminum salts are a familiar example) and remain in some vaccines [5]. The long‑running public discussion shows aluminum is used in vaccines when developers use antigen types that need adjuvants, but the two dominant mRNA COVID‑19 vaccines were designed without traditional adjuvants such as aluminum salts; those mRNA shots rely on lipid nanoparticles for delivery rather than classic adjuvants (p1_s3; p5_sni—note: fact sheets referenced by FDA list exact ingredients) [6]. Different COVID vaccine platforms therefore differ: some protein subunit or traditional formulations may include adjuvants while mRNA products do not [5] [6].
3. Where do fetal‑derived cell lines enter the story — development, testing, manufacturing stages
Multiple reputable explainers and public health outlets document that fetal‑origin immortalized cell lines (for example HEK293 or PER.C6) were used in testing, development or manufacturing for certain COVID vaccines. The mRNA vaccines from Pfizer and Moderna were not produced using fetal‑tissue‑derived cell lines in their manufacturing processes, though fetal cell lines were used in some testing during research and development [1] [3]. Johnson & Johnson (Janssen) and AstraZeneca used fetal‑origin cell lines in production or development; fact checks have verified that J&J’s vaccine involved such lines [7] [2]. Novavax has stated it did not use HEK293 or PER.C6 in development or manufacturing, though legal and analysis pieces note disputes and close reading of studies by critics [8].
4. What “contain” means — technical versus ethical claims
Wording matters. Some sources emphasize vaccines do not “contain” fetal tissue in the final product: cell lines used decades ago are thousands of generations removed from original fetal tissue and are not intact fetal organs or tissue in vials [3] [9]. Other commentators argue that saying “fetal cells were used” is accurate when referring to stages of testing or production even if no fetal cells remain in the finished dose; debate between semantic and moral framings has driven religious and ethical objections [10] [11].
5. How official agencies communicate ingredient information
The FDA explicitly directs people to vaccine fact sheets that list ingredients for each authorized product; those documents are the authoritative public source for preservatives and excipients in any given lot or formulation [6]. Public advisory panels and news coverage have continued to discuss contaminants, adjuvants and vaccine ingredients at ACIP and other meetings, reflecting ongoing scrutiny and public interest [12] [5].
6. Competing viewpoints and lingering questions
Public health sources (FDA, CDC summaries cited by reporting) present the technical details that mRNA vaccines weren’t produced in fetal cell factories and that adjuvants like aluminum are not in mRNA shots; advocacy and religious groups emphasize moral proximity to any use of fetal‑origin cell lines in development, and some legal observers contest manufacturer statements about specific products such as Novavax [1] [8] [11]. Investigations and debates over safety signals, labeling and regulatory changes in 2025 show ingredient and safety conversation remains politically charged even as clinical studies continue to support vaccine benefits [13] [14] [15].
Limitations: this summary relies on the provided reporting and public‑facing fact sheets referenced therein; for the precise ingredient list of any specific vaccine lot or updated 2025‑2026 formulation, consult the FDA fact sheet or manufacturer label cited by the FDA [6].